Cannabist Co Holdings Inc., formerly Columbia Care, is a U.S. cannabis operator that cultivates, manufactures, and sells cannabis products through a multi-state network of dispensaries and production facilities. The company operates in 12 U.S. jurisdictions and runs 71 facilities, including 53 dispensaries and 18 cultivation/manufacturing sites under development or in operation. Its business spans both medical and adult-use cannabis, with retail sold under the Cannabist brand and products distributed through its own stores and branded product lines. The company’s portfolio includes flower, edibles, oils, and tablets, along with a set of house brands such as dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber.
5,8 %
36,7 %
−23,1 %
−10,3 %
0.85
0.44
| % | |
|---|---|
| Retail dispensaries | 45% Cannabist-branded stores that sell cannabis products directly to medical patients and adult-use consumers. |
| Cultivation and manufacturing | 30% Growing, processing, and manufacturing operations that supply the company’s own retail network and wholesale channels. |
| Branded cannabis products | 20% Packaged flower, edibles, oils, tablets, and other products sold under proprietary brands. |
| Wholesale and related services | 5% Product sales and related support services to third-party dispensaries and market participants where permitted. |
The company serves two core end markets: medical cannabis patients and adult-use consumers...
Patients in licensed jurisdictions who buy cannabis products for symptom relief and ongoing treatment needs.
Recreational customers purchasing through the Cannabist retail network in legalized markets.
Other licensed operators and dispensaries that buy product supply where the company can sell outside its own stores.
Customers who seek specific product lines such as dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber.
Cannabist operates in 12 U.S. jurisdictions, making its business highly dependent on state-by-state cannabis regulation...
The company’s near-term focus is on preserving liquidity, controlling operating expenses, and improving operating...
The company has sustained losses and needs capital to fund operations, debt obligations, and capital expenditures.
Margins and cash flow are pressured by inflation, regulatory complexity, and a challenging cannabis market.
Growth depends on adding sales volume in new and existing jurisdictions without overextending the balance sheet.
The most material company-specific risk is liquidity and going-concern pressure, as management discloses substantial...
The company has sustained significant losses, negative operating cash flow, limited cash, and substantial debt obligations, creating doubt about its ability to continue without additional financing.
Management states the 2025 Debt Transaction may be delayed or not completed due to litigation, which could trigger significant liquidity challenges.
Revenue and operating permissions depend on state and federal cannabis laws, which can change and affect store openings, product sales, and compliance costs.
The company says it may have difficulty retaining or hiring qualified personnel due to challenging financial conditions.
Rising inflation can increase labor, energy, and supply costs, while the company may not be able to pass those increases through to customers.
PLNH · Agricultural Production-Crops
TCRG · Medicinal Chemicals & Botanical Products
CHUC · Medicinal Chemicals & Botanical Products
TRLV · Medicinal Chemicals & Botanical Products
CBDY · Medicinal Chemicals & Botanical Products
CPMD · Pharmaceutical Preparations
: 28/04/2026